Enzymotec Ltd., a developer, manufacturer and marketer of innovative bio-functional lipid ingredients,  has received a key patent by the US Patent and Trademark Office (USPTO) for its composition of Vayacog and its use in age-associated memory impairment and mild cognitive impairment.

"We are very pleased with the patent granted related to Vayacog, one of our leading products intended for the dietary management of disorders related to cognitive or mental conditions. We believe this patent is evidence of Enzymotec's leading research and development initiatives and strengthens Vayacog's position in the United States and other territories," said Dr Ariel Katz, president and chief executive officer of Enzymotec Ltd. "We remain focused on building our intellectual property assets and delivering premier products to our customers around the world."

Vayacog is an orally administered prescription medical food for the clinical dietary management of certain lipid imbalances associated with early memory impairment.

The Company has been granted over 50 patents and has applications for more than 100 additional patents pending worldwide.

Enzymotec develops, manufactures and markets innovative bio-functional lipid ingredients, as well as final products, based on sophisticated processes and technologies.